Change Pain Latin America – new initiative established to enhance management of patients with chronic pain in Latin America  by Garcia, João Batista Santos
RL
C
i
m
i
D
I
t
o
p
o
a
p
p
a
(
B
V
p
a
a
p
o
r
M
c
t
t
d
t
p
i
a
i
a
C
i
o
w
r
p
t
0ev Bras Anestesiol. 2014;64(2):140--144
REVISTA
BRASILEIRA  DE
ANESTESIOLOGIA Ofﬁcial  Publication  of the  Brazilian  Society  of  Anesthesiologywww.sba.com.br
ETTERS TO THE EDITOR
hange  Pain Latin America -- new
nitiative  established to enhance
contribute  to  the  unmet  medical  needs  of  patients  with
chronic pain  in  Latin  America.b
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uanagement  of patients with chronic pain
n  Latin America
ear  Editor,
 wish  to  advise  you  of  the  formation  of  a  new  scien-
iﬁc advisory  panel,  committed  to  enhancing  the  quality
f life  of  chronic  pain  patients  in  Latin  America.  The
anel was  formed  in  response  to  the  encouraging  outcomes
bserved with  the  Change  Pain  Europe  program,  which
imed to  identify  the  unmet  needs  of  European  chronic
ain patients  and  provide  best  practice  solutions  to  improve
atient outcomes.  The  panel  of  regional  experts  is  driving
 pan-Latin  American  initiative:  Change  Pain  Latin  America
CPLA).
The CPLA  Advisory  Panel  comprises  17  experts  from
razil, Chile,  Colombia,  Costa  Rica,  Ecuador,  Mexico,  Peru,
enezuela and  Spain,  who  work  across  a  variety  of  clinical
ain-related specialties  (Table  1).  Panel  members  are
pplying their  knowledge  and  experience  to  highlight  and
ddress the  unmet  medical  needs  associated  with  treating
atients with  chronic  pain  in  Latin  America  and  overcome
bstacles to  improve  best  practice  and  outcomes  in  this
egion. The  inaugural  meeting  of  the  panel  took  place  in
iami (June  28--29,  2012)  where  discussions  focused  on
urrent treatment  paradigms  in  Latin  America  and  barriers
o effective  patient  management.  During  this  meeting,
he objectives  for  CPLA  were  determined  after  robust
iscussions, and  accepted  with  consensual  agreement  from
he panel  members  (Table  2).
While  suboptimal  management  of  patients  with  chronic
ain is  a  global  issue,  factors  that  contribute  to  this  problem
n Latin  America  include  gaps  in  physicians’  understanding
nd associated  pain  management  misconceptions.  Patients
n Latin  America  often  misunderstand  the  risks  associ-
ted with  analgesics,  making  patient  education  a  priority.
onsequently, healthcare  professionals  in  the  region  have
nadequate knowledge  of  the  advantages  and  disadvantages
f opioids,  and  the  correct  dosing  of  these  medications,
hich limits  appropriate  prescribing.  Other  signiﬁcant  bar-
iers include  limited  patient  access  to  medications  and/or
ain specialists  and  specialist  facilities,  as  well  as  restric-
ive government  healthcare  policies.  All  of  these  factors
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er 9--10,  2012),  the  panel  unveiled  several  key  initiatives
esigned to  address  these  unmet  needs.  To  help  improve
atient management,  panel  members  are  now  reviewing
nternational chronic  pain  guidelines  to  identify  manage-
ent strategies  that  are  most  relevant  to  Latin  America.
he next  step  will  be  to  provide  physicians  throughout  the
egion with  clear  treatment  recommendations  based  on  this
esearch to  facilitate  the  adoption  of  uniform  best  practice
hroughout the  region.  The  ﬁrst  set  of  recommendations
ill focus  on  chronic  low  back  pain.  The  unmet  need  for
ducation among  physicians  is  also  being  addressed  via  an
nline ‘Meeting  in  a  Box’  tool  comprising  an  up-to-date
lide library  and  meeting  organization  resources  for  the
ducation of  groups  of  physicians  on  key  issues  in  chronic
ain at  local  meetings.  In  addition,  newsletters  detailing
ey regional  issues  in  chronic  pain  management  and  activ-
ties planned  by  the  CPLA  panel  to  help  address  these
ssues, will  be  distributed  to  the  wider  healthcare  commu-
ity.
Part of  the  panel’s  efforts  will  focus  on  gaining  a  bet-
er understanding  of  the  burden  of  chronic  pain  in  the
atin American  region.  Panel  members  have  conducted
 meta-analysis  of  available  epidemiological  data,  which
stablished the  prevalence  of  chronic  lower  back  pain  in
he region  and  highlighted  the  need  for  more  robust  stud-
es. To  support  this,  the  panel  discussed  a  new  burden
f disease  protocol  that  is  designed  to  quantify  health-
are resource  consumption  by  chronic  pain  patients  across
atin America.  The  data  generated  should  provide  consistent
stimates of  both  the  direct  and  indirect  costs  associ-
ted with  this  burden  in  all  member  countries,  which  it
s hoped  will  inform  better  resource  management  in  the
rea. In  addition,  information  on  prescribing  and  diagno-
is habits  among  physicians  in  Mexico  will  be  published  in
he near  future.  If  the  survey  is  extended  to  include  the
ntire region  and  repeated  on  a  yearly  basis,  it  will  allow
hanges in  clinical  practice  across  Latin  America  to  be  doc-
mented.
The CPLA  panel  will  establish  working  groups  to  focus
n meeting  accepted  consensus  objectives.  Practical  strate-
ies are  required  to  break  down  regional-speciﬁc  barriers  to
he effective  management  of  patients  with  chronic  pain.
mproved training  and  ongoing  education  of  healthcare
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Table  1  Change  Pain  Latin  America  Advisory  Panel
members.
Argelia
Lara-Solares
Mexico  Anesthesiology,
pain  management
and palliative  care
José Alberto
Flores  Cantisani
Mexico  Anesthesiology,
pain  management
and palliative  care
César
Amescua-García
Mexico  Anesthesiology,
pain  management
and palliative  care
María del  Rocío
Guillén Nún˜ez
Mexico  Anesthesiology,
pain  management
and palliative  care
Aziza Jreige
Iskandar
Venezuela  Physical
rehabilitation
Patricia  Bonilla Venezuela  Anesthesiology,
pain  management
and palliative  care
João Batista
Santos  Garcia
Brazil  Anesthesiology,
pain  management
and palliative  care
Osvandré Lech  Brazil  Orthopedics
Durval  Campos
Kraychete
Brazil  Anesthesiology
and  pain
management
María Antonieta
Rico
Chile  Anesthesiology,
pain  management
and palliative  care
John Jairo
Hernández-
Castro
Colombia  Neurosurgery,  pain
management and
palliative care
Frantz Colimon  Colombia  Anesthesiology
and  pain
management
Carlos  Guerrero  Colombia  Anesthesiology,
pain  management
and palliative  care
William Delgado
Barrera
Costa  Rica  Anesthesiology
Manuel
Sempértegui
Gallegos
Ecuador  Anesthesiology
and  pain
management
María Berenguel
Cook
Peru  Anesthesiology,
pain  management
and palliative  care
Concepción Pérez Spain  Anesthesiology
Table  2  Objectives  of  the  Change  Pain  Latin  America  Advi-
sory Panel.
•  Identify  the  relevant  factors  inﬂuencing  the  treatment
of  pain  and  the  decision  makers  across  Latin  America
•  Understand  the  relevant  factors/reasons  behind  the
current  pain  treatment  paradigm
• Identify  the  levers  that  can  be  used  to  modify  the
situation
•  Establish  the  link  between  medical  practice  and
theory  in  the  management  of  chronic  pain
•  Establish  the  real  unmet  needs  in  the  treatment  of
chronic  pain  in  Latin  America
• Better  understand  the  reality  of  chronic  pain  patients
today
•  Find  consensus  on  the  challenges  in  managing  chronic
pain  from  a  physician’s  perspective
• Evaluate  the  need  to  educate  to  raise  the  awareness
on  best  practice  in  the  management  of  chronic  pain
•  Assess  the  need  to  enhance  communication  between
physicians  and  patients  as  a  way  to  improve  the
management  of  pain
• Develop  solutions  based  on  research  data  and  experts’
opinion  supporting  more  effective  and  efﬁcient  pain
management
•  Increase  knowledge  and  provide  appropriate  tools  to
improve  pain  diagnosis
• Eliminate  opiophobia  through  education  of  healthcare
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professionals  and  providers  are  needed  to  improve  diagnos-
tic and  treatment  decisions.  This  will  increase  appropriate
prescribing of  currently  available  analgesics  and  the
acceptance of  new  analgesic  technologies  as  they  are
approved across  Latin  America.  A  greater  understand-
ing of  the  burden  of  pain  in  Latin  America  is  also
critical moving  forward.  By  generating  robust  epidemio-
logic and  pharmacoeconomic  data  for  the  region,  CPLA
will assist  efforts  to  predict  how  the  needs  for  anal-
gesics will  change  in  future.  These  new  data  and  current
c
L
Eprofessionals  and  patients  on  opioid  treatment
vidence  will  also  be  vital  in  endeavors  to  facilitate
reater dialogue  with  national  government  decision-makers,
nd help  reshape  healthcare  policy  leading  to  the  best
ossible care  for  patients  with  chronic  pain  in  Latin
merica.
To help  highlight  the  relevant  issues  in  Latin  America,
PLA is  seeking  to  partner  with  established  national  pain
rganizations across  the  region.  A  familiar  approach  assisted
hange Pain  Europe,  which  is  endorsed  by  the  European
ederation of  IASP® Chapters  (EFIC),  in  achieving  its  aims.
The CPLA  Advisory  Panel  is  next  scheduled  to  meet  in
ay 2013,  with  a  further  meeting  planned  for  later  in
013. Practical  materials  are  being  developed  and  will  be
isseminated at  a  national  level.  For  further  information
bout CPLA  and  the  CPLA  panel,  please  visit  the  website
t www.latamchangepain.com.
onﬂicts of interest
hange  Pain  Latin  America  is  supported  by  an  educational
rant from  Grünenthal.
oão Batista  Santos  Garciaa,b,c,1
Sociedade  Brasileira  de  Estudo  da  Dor,  São  Paulo,  SP,
razil
Universidade  Federal  do  Maranhão,  São  Luís,  MA,  Brazil
Instituto  Maranhense  de  Oncologia  Aldenora  Belo,  São
uís,  MA,  Brazil
-mail: jbgarcia@uol.com.br
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On  behalf  of  The  Change  Pain  Latin  America  Advisory
anel: Argelia  Lara-Solares,  José  Alberto  Flores  Cantisani,
ésar Amescua-García,  María  del  Rocío  Guillén  Nún˜ez,
ziza Jreige  Iskandar,  Patricia  Bonilla,  Osvandré  Lech,  Dur-
al Campos  Kraychete,  María  Antonieta  Rico,  John  Jairo
Hernández-Castro,  Frantz  Colimon,  Carlos  Guerrero,  William
Delgado Barrera,  Manuel  Sempértegui  Gallegos,  María
Berenguel Cook,  João  Batista  Santos  Garcia,  Concepción
Pérez Hernández.
http://dx.doi.org/10.1016/j.bjane.2013.03.004
ontraction versus contracture and
entronuclear  myopathy versus central
art  myopathy in malignant hyperthermia
ear  Editor,
e read  with  great  interest  the  review  article  by  Cor-
eia et  al.  ‘‘Malignant  hyperthermia:  clinical  and  molecular
spects’’1 (Hipertermia  maligna:  aspectos  moleculares  e
línicos)  and  would  like  to  comment  on  some  aspects.
In  the  section  ‘‘Malignant  hyperthermia’’,  item
‘Contraction to  exposure  to  halothane-caffeine  (TCHC)
est’’, Correia  et  al.  use  the  term  ‘‘contraction’’  instead
f the  original  term  ‘‘contracture’’.  The  test  for  diagnosis
f susceptibility  to  malignant  hyperthermia  (MH)  is  based
n an  abnormal  contracture  response  after  administration
f caffeine/halothane,  and  not  on  the  normal  response  of
uscle contraction  after  electrical  stimulation,  which  is
pplied throughout  the  test  to  prove  viability  of  the  muscle
ragment tested.  Fig.  1  shows  the  difference  between
ontraction and  contracture  in  the  chart  of  a  positive  test  in
 patient  susceptible  to  MH.  Thus,  the  nomenclature  should
e ‘‘contracture  test’’  in  English  and  teste  de  contratura
n Portuguese.2--4
Also  in  this  subsection,  we  emphasize  that  the  cutoff  lev-
ls of  TCHC  cited  correspond  to  values  used  in  the  U.S.  group
f HM  (MHAUS  --  www.mhaus.org) protocol.  Moreover,  the
rotocol  of  the  European  MH  Group  (EMHG  --  www.emhg.org)
iffers from  the  U.S.  one  in  additional  aspects  that  were
ot mentioned,  such  as  the  number  of  fragments  tested  (six
n the  U.S.  and  four  in  the  European  protocol),  halothane
dministration (single  dose  of  3%  in  the  U.S.  and  an  increas-
ng dose  from  0.5%  to  3%  in  the  European  protocol)  and  ﬁnally
he cutoff,  which  is  0.2  g  to  for  halothane  2%  and  0.2  g  for
affeine 2  mm  in  the  European  protocol.5,6
Unlike  that  noted  by  Correia  et  al.,  in  Brazil  the  Cedhima
Center for  the  Study,  Diagnosis  and  Research  for  Malignant
yperthermia), Escola  Paulista  de  Medicina,  Universidade
ederal de  São  Paulo  (UNIFESP)  uses  the  European  MH  group
rotocol for  in  vitro  muscle  contracture  testing  (IVCT).4
In  the  same  section  ‘‘Malignant  hyperthermia’’,  item
‘Treatment’’, Correia  et  al.  include  as  an  indicated  mea-
ure the  ‘‘Replacement  of  anesthesia  circuit  by  other  circuit
ncontaminated by  anesthetic  agent’’.  It  is  important  to
mphasize here  that  there  is  no  indication  for  this  measure
uring the  treatment  of  a  crisis,  but  only  in  the  preparation
although  Correia  et  al.  state  that  the  modern  clinical  use
of dantrolene  is  restricted  to  malignant  hyperthermia,  this
drug is  still  employed  in  the  management  of  spasticity.8
Furthermore,  the  maintenance  of  dantrolene  for  24--48  h
after the  initial  treatment  of  HM  crisis  is  important  to  avoid
1 min
0.6 g
0.5% 1%
Figure  1  In  vitro  muscle  contracture  test  (IVCT)  in  response
to halothane.  The  two  lower  arrows  indicate  the  time  at  which
the drug  was  added.  The  upper  arrow  indicates  the  lines  thatf the  anesthetic  machine  for  anesthesia  in  a  patient  with  a
istory of  HM.  At  the  time  of  a  MH  crisis  we  must  ‘‘disconnect
he vaporizer,  but  with  no  waste  of  time  changing  the  cir-
uit or  the  anesthetic  machine’’.7 In  ‘‘Dantrolene’’  item,
c
u
b
torrespond to  muscle  contractions  triggered  by  electrical  stim-
lation. The  lateral  double  arrow  indicates  the  ascension  of  the
ase  line,  which  corresponds  to  an  abnormal  muscle  contrac-
ure.
